Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks! I try to effectively communicate. Really I’m attempting to demonstrate personal conviction and advocacy here. What is in my control? What can I actively do as a shareholder in a company with successful trial results, while that same company is being attacked unfairly, and all for control and money. I’m a retired therapist looking for some good in the world and call out injustice where and when I see it and do something.
Have an awesome Monday!
Margaret
Thanks. When I communicate I want to be heard and understood. I don’t believe effective communication includes derogatory wording. My anger at the stock price manipulation on the 10th motivated me to write to whomever could get the word out on the successful trial and do something about the stock price manipulators. I can separate my anger from the black and white. My words represent me in the Ethernet and I want to represent myself honestly and respectfully of others. So once again, the DC-Vax L trial was successful and did better than the current SOC. The FDA will approve DC-Vac L (imo).
Margaret
GLTA Patients
Thanks Sojo, that means a lot coming from you. I've learned so much from your posts and enjoy your experienced NWBO charting analysis.
Keep up the great work!
Margaret
I believe they have it all scheduled, a plan and we will know more by 06/30/2022 with ASCO, ASM and Journal Publication (fingers crossed). Let's wait until 06/30/2022 to see if it was even remotely a "bonehead move". I believe it's a bonehead move to throw mud at the company. The stock price manipulation was going to happen with release of the trial results and the market manipulators took the price up over the last month and then dropped it back down to the current level to deceive people into thinking the trial failed. The stock price started to drop BEFORE the successful trial results were presented. The science is solid, the company has a plan and let's see what has transpired by 06/30/2022. FDA will approve DC-Vax L as the new SOC (imo) and I'm excited to see where the company goes in the future.
Know what you hold,
Margaret
That the stock price manipulators are hard at work. The science is solid and DC-Vax L will be approved by the FDA and become the new SOC.
Margaret
(IMO)
GLTA PATIENTS
Email to Josh at Endpoint News:
josh@endpointsnews.com
Josh,
I just read an article you wrote on Northwest Biotherapeutics May 13, 2021. I wanted to recommend another related story which is two-fold, first the successful trial and secondly the stock price manipulation as follows:
At New York Academy of Sciences on May 10, 2022 there was a scientific presentation of DC-Vax L which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack it. They had amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. The stock price crashed before the statistics were presented, and continued even with exceptional news about a cure for cancers. A story about the trial success, stock price manipulation and the mechanisms still in place to promote this nefarious activity. How this illegal behavior destroys the biotech industry from getting new treatments to the patients who need the treatment. This company is also working on a cancer platform to treat a broad variety of cancers in the future. If they are financially choked before commercialization then the people who manipulate the stock for their own greedy motivations kill an effective treatment for cancer from getting to the patients. I am a small investor in Northwest Biotherapeutics so my opinion is biased. I would encourage investigating this story and other stories of killing companies illegally through Wall Street’s shorting practices.
Thanks for your time,
Margaret Monson
Thank you. I can only advocate in my small way. I have the ability to communicate and I stand behind the science, period. The FDA will approve this as the new SOC (of course this is my opinion and not a fact...yet) and the noise will go away to other more vulnerable biotech companies unfortunately. I hope, with this last obvious stock price manipulation, that the SEC and the DOJ hold those who are involved in this accountable. Including all the libel published (both author and publisher), that they are brought to justice. NWBO has navigated these treacherous waters so far and I believe the tides are turning...we still have 6 1/2 weeks until the end of June. I feel that we will have a lot more answers by 6/30 with ASCO, ASM and Journal publication (fingers crossed).
Margaret
Sent this just now to AACR:
cancerdiscovery@aacr.org
Article correction for DC-Vax L
At New York Academy of Sciences on May 10, 2022 there was a scientific presentation of DC-Vax L which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack the cancer. DC-Vax L showed amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. Both the primary and secondary endpoints for overall survival inn new and recurrent GBM patients were statistically significant.
Below is a link to the Phase III trial results. Please have your article rewritten yesterday to reflect the positive results of DC-Vax L as well as a retraction of the incorrect statistics included in your article. The article reflects an incorrect data analysis. I would suggest talking to Dr. Mulholland or Dr. Liau to confirm the accurate results as well as the information provided that progression free survival (pfs) is no longer an effective assessment with regards to GBM trials.
This company is also working on a cancer platform to treat a broad variety of cancers in the future. Northwest Biotherapeutics is trying to bring effective cancer treatments to the world and this is news worthy.
Do you want to be part of the problem and stock price manipulation or do you want to report the truth?
Thank you for your time in reviewing the data, correcting the article and publishing a retraction.
Margaret Monson
https://virtualtrials.org/dcvax/dcvax.pdf
Thank you TDD.
In the presentation they were speaking of the trial halt from 2008 to 2011. From my experience with statistical papers, they will address the other trial halt in the paper. That will need to be addressed as would any trial anomalies.
Bottom line: DC-Vax L works and should be approved by all the regulators.
Margaret
Dr. Mulholland at 8:15 in the P3 presentation from 5/10 communicates that the suspension of the trial was due to financial reasons:
“…and the reason for the suspension was nothing to do with safety or any of the reasons, it was purely financial reasons.”
I totally agree too. NWBO has an effective cancer treatment to get to commercialization. We will know more at both ASCO and the ASM. What is happening, what we are currently doing about it and where we going in the future as a company.
Know What You Hold,
Margaret
GLTA patients
All of this will happen in the next 7 weeks.
Sunday’s webinar by Al Musela:
5/15/2022: Sunday 7pm Eastern Time.
Topic: "Speeding up the search for the cure of brain tumors!"
Speaker:Al Musella, DPM President and founder of the Musella Foundation For Brain Tumor Research & Information, Inc.
5/22/2022: Sunday 7pm Eastern Time.
Topic: "Stereotactic radiosurgery: the treatment of choice for people with vestibular schwannomas"
Speaker:Michael Schulder, MD is the vice chair of neurosurgery at North Shore University Hospital and Long Island Jewish Medical Center. He is also the director of the Brain Tumor Center at the Institute for Neurology and Neurosurgery-which treats more than 600 patients annually-and co-director of the Center for Stereotactic Radiosurgery, where his team offers the latest treatment technologies. His research focuses on improving methods of image guidance for brain tumor surgery, and on new techniques for radiosurgery.
Thank you for your continued DD. The foundation continues to be laid for regulatory approval. Expect fud twisting the change in SAP. It’ll continue their false lies about when the endpoints were changed. What is angering about the Fud is Dr. Mulholland clearly explained at the 8:00 minute mark why Progression Free Survival (PFS) was no longer an applicable endpoint, listen to his explanation for the logic in changing the trial endpoints. At 12:45 Dr. Mulholland clearly states the two Ongoing Survival (OS) end points for newly and recurrent GBM were approved endpoint changed prior to unblinding the trial results. Dr. Mulholland’s presentation with Q&A is linked below.
Margaret
I’m writing to media outlets too. The people within the medical community are reporting the news about DC-Vax L’s effectiveness in Ongoing Survival in newly and recurrent GBM. They are reporting DC-Vax L is statistically significantly more effective than the current standard of care in both groups of patients. The individuals in the media industry with nationwide and worldwide exposure will find out the news from the medical experts. I can attempt to bridge the gap between the medical and media industries by doing my part with the communication tools available to me. Regardless of the outcome of my attempts, the fact is I tried and I’m okay with my advocacy of the DC-Vax platform.
“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has.”
Attributed to Margaret Mead
Margaret
Contacting White House from previous posts on Thursday. Anyone wanting to use any or all of my letter feel free to use.
Margaret
Thursday, May 12, 2022
Post# of 472598 Go
For anyone wanting to contact the White House through President Biden’s Moonshot Initiative to cure cancer here is the link to the page to share personal cancer stories and videos, actions, etc…
https://www.whitehouse.gov/cancermoonshot/
Post# of 472599 Go
Letter to President Biden:
Dear Mr. President,
At New York Academy of Sciences yesterday there was a scientific presentation of DC-VaxL which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack the cancer. DC-VaxL showed amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. The stock price crashed even with exceptional news about a cure for cancers. Wall Street needs to be stopped and their mechanisms still in place to promote stock price manipulation activity. This potentially could destroy this biotech company (Northwest Biotherapeutics) from getting new interventions to the patients who desperately need these treatments. This company is also working on a cancer platform to treat a broad variety of cancers in the future. If they are financially choked before commercialization then the people who illegally manipulate the stock price don’t have to pay for the criminal financial havoc they created to destroy a company. I am reaching out to you personally, as I believe this company’s innovative advancements in cancer treatment aligns with your Moonshot Initiative in finding a cure for cancer.
Thank you for your time,
Margaret Monson
Historical Short Volume Data for NWBO
Date / Volume / Short Volume / % of Vol Shorted
May 11 / 13,949,046 / 6,309,589 / 45.23
May 10 / 76,966,370 / 15,072,243 /19.58
May 09 / 11,997,726 / 7,297,501 / 60.82
May 06 / 7,927,571 / 5,330,145 / 67.24
May 05 / 11,658,028 / 6,554,064 / 56.22
May 04 / 9,545,498 / 4,902,658 / 51.36
May 03 / 8,310,611 / 4,881,899 / 58.74
https://www.otcshortreport.com/company/NWBO
This is a report of the legal shorting volume going on currently.
Margaret
Thanks for the reminder. The stock price was last around .77 on 4/6/2022 and posters were getting excited about the release of TLD. The anticipation was starting for ASCO and speculating on how NWBO would rollout news. Now we have TLD with all endpoints met. Let’s get back to anticipation and watching the rollout from the company once the embargo is lifted.
Margaret
For anyone wanting to contact the White House through President Biden’s Moonshot Initiative to cure cancer here is the link to the page to share personal cancer stories and videos, actions, etc…
https://www.whitehouse.gov/cancermoonshot/
Tweet to AF:
At NYAS 5/10/22 a scientific presentation of DC-Vax L which is an immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack it. They presented an effective treatment. Investigate stock manipulation. $NWBO #DCVax
At NYAS 5/10/22 a scientific presentation of DC-Vax L which is an immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack it. They presented an effective treatment. Investigate stock manipulation. $NWBO #DCVax
— Margaret Monson (@MargaretMonson3) May 12, 2022
Letter to President Biden:
Dear Mr. President,
At New York Academy of Sciences yesterday there was a scientific presentation of DC-VaxL which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack the cancer. DC-VaxL showed amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. The stock price crashed even with exceptional news about a cure for cancers. Wall Street needs to be stopped and their mechanisms still in place to promote stock price manipulation activity. This potentially could destroy this biotech company (Northwest Biotherapeutics) from getting new interventions to the patients who desperately need these treatments. This company is also working on a cancer platform to treat a broad variety of cancers in the future. If they are financially choked before commercialization then the people who illegally manipulate the stock price don’t have to pay for the criminal financial havoc they created to destroy a company. I am reaching out to you personally, as I believe this company’s innovative advancements in cancer treatment aligns with your Moonshot Initiative in finding a cure for cancer.
Thank you for your time,
Margaret Monson
Thanks!
Thanks to all who shine a light on truth and the science of DC-Vax. I don’t have medical or investment expertise. I know my sphere of influence and what I can do to aid in better patient care for cancer. I can attempt to contact those who have a greater sphere of influence than I do. I’m okay with that being my contribution to assisting cancer patients that need this treatment approved.
I just want national media to investigate why the stock price plummeted on excellent news.
"Never doubt that a small group of thoughtful committed individuals can change the world. In fact, it's the only thing that ever has."
Attributed to Margaret Mead but it is not confirmed who stated this phrase.
To answer your question. It might not be the right media platform. However, look at who some of his close friends are: Anderson Cooper, John Stewart and John Oliver.
I’ve also tweeted to Stephen Colbert the following:
At NYAS 5/10/22 a scientific presentation of DC-Vax L which is an immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack it. They presented an effective treatment. Investigate illegal shorting. $NWBO #DCVax
Thank you for posting this video with the Q&A Dr. Bala!
Margaret
Emailed John Oliver’s show the following:
Michelle.Goldstein@warnermedia.com
At New York Academy of Sciences yesterday there was a scientific presentation of DC-VaxL which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack it. They had amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. The stock price crashed even with exceptional news about a cure for cancers. A story about illegal shorting and the mechanisms still in place to promote this nefarious activity and how it can potentially destroy the biotech industry from getting new treatments to the patients who need the treatment. This company is also working on a cancer platform to treat a broad variety of cancers in the future. If they are financially choked before commercialization then the people who illegally short the stock don’t have to financial pay for the phantom stocks they created. I am a small investor in Northwest Biotherapeutics so my opinion is biased. I would encourage investigating this story and other stories of killing companies illegally through Wall Street’s illegal shorting.
Thanks for your time,
Margaret Monson
Thank you as I think the Q&A portion adds context and value to the scientific presentation.
The video doesn’t include the Q&A afterwards.
My impression is was Dr. Mulholland could speak to the P3 trial only. Dr. Bosch appeared to provide more details and answer questions that probably would have been answered by Dr. Liau to the items outside the scope of presentation and further studies that are currently being run at UCLA. Being that it was a last minute change in speakers (and he being remote) NYAS wasn’t set up for this presentation Q&A to be split. I thought they did well given the unexpected change in speakers.
I agree the company is still under an embargo of some nature. We all must do our own DD, for me the company understands what they continue to be up against and have a plan to get DC-Vax to commercialization. What would keep them from posting on their website ( just like they did with the interim presentation) yesterday’s presentation except for an embargo?
Margaret
During the Q&A yesterday there was a question about the combo trials. No specific numbers given, (as this was off topic for P3 study presentation) of interest to me was the excitement about the synergy between the two interventions. This was my impression in seeing the presentation. I did not record the presentation so I was wondering other posters thoughts on the Q&A and in particular the part about the combo trials.
Margaret
Me too!!!! Happy happy dancing going on here!!! I don’t care about the price today. Given what shorts did with the unblinded interim results presentation, I expected them to do the same now. It doesn’t matter as they can’t stop NWBO’s regulatory approval and commercialization of DC-Vax. This drug will make it to patients as SOC. IMO
Margaret
Meaningful statistical significance in both new and recurrent gbm.
Primary and secondary endpoints met.
Updated time at NYAS. The conference is on a break and will resume on time at 11:10.
NYAS conference with the Q&A’s is currently running about 10 minutes later than what’s on the schedule FYI.
Here is part of the SEC rules on public disclosure. The rules do not mention that the initial announcement has to be free. It does handle requirements of a company doing simultaneous disclosure in the case of selective groups receiving information not publicly disclosed. With who is running NWBO, I’m certain they are aware of these rules.
“for an intentional selective disclosure, the issuer must make public disclosure simultaneously; for a non-intentional disclosure, the issuer must make public disclosure promptly.”
https://www.sec.gov/rules/final/33-7881.htm